	US 12,324,441 B2
	Hyperimmunized egg product for treatment or prevention of coronavirus infection
Subramanian V. Iyer, Royal Palm Beach, FL (US); Satishchandran Chandrasekhar, Jupiter, FL (US); Uday Saxena, Bengaluru (IN); and Gopi Kadiyala, Karnataka (IN)
Assigned to Lay Sciences, Inc., Jupiter, FL (US)
Filed by LAY SCIENCES, INC., Jupiter, FL (US)
Filed on Apr. 28, 2023, as Appl. No. 18/308,934.
Application 18/308,934 is a continuation of application No. 17/693,280, filed on Mar. 11, 2022, granted, now 11,701,423.
Claims priority of provisional application 63/160,155, filed on Mar. 12, 2021.
Prior Publication US 2023/0285547 A1, Sep. 14, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/215 (2006.01); A23B 5/00 (2006.01); A23B 5/03 (2006.01); C07K 16/10 (2006.01); A61K 39/00 (2006.01)

CPC A23B 5/03 (2013.01) [A23B 5/00 (2013.01); A61K 39/215 (2013.01); C07K 16/1002 (2023.08); C07K 16/1003 (2023.08); A61K 2039/552 (2013.01)]

14 Claims

1. A hyperimmunized egg produced by an animal that has been hyperimmunized with an antigen consisting of the amino acid sequence of SEQ ID NO: 19,

wherein the level of antibodies to the antigen in the hyperimmunized egg is increased relative to an egg from an animal that has not been hyperimmunized.